ZA200700395B - Novel formulation for L-tryptophane comprising carbidopa/benserazide - Google Patents
Novel formulation for L-tryptophane comprising carbidopa/benserazide Download PDFInfo
- Publication number
- ZA200700395B ZA200700395B ZA200700395A ZA200700395A ZA200700395B ZA 200700395 B ZA200700395 B ZA 200700395B ZA 200700395 A ZA200700395 A ZA 200700395A ZA 200700395 A ZA200700395 A ZA 200700395A ZA 200700395 B ZA200700395 B ZA 200700395B
- Authority
- ZA
- South Africa
- Prior art keywords
- tryptophan
- inhibitor
- peripheral
- retarded
- benserazide
- Prior art date
Links
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 title claims abstract description 117
- 229960004799 tryptophan Drugs 0.000 title claims abstract description 63
- 238000009472 formulation Methods 0.000 title claims abstract description 10
- 239000000203 mixture Substances 0.000 title claims abstract description 10
- BNQDCRGUHNALGH-UHFFFAOYSA-N benserazide Chemical compound OCC(N)C(=O)NNCC1=CC=C(O)C(O)=C1O BNQDCRGUHNALGH-UHFFFAOYSA-N 0.000 title claims description 25
- 229960000911 benserazide Drugs 0.000 title claims description 24
- 229960004205 carbidopa Drugs 0.000 title claims description 11
- TZFNLOMSOLWIDK-JTQLQIEISA-N carbidopa (anhydrous) Chemical compound NN[C@@](C(O)=O)(C)CC1=CC=C(O)C(O)=C1 TZFNLOMSOLWIDK-JTQLQIEISA-N 0.000 title claims description 11
- QZAYGJVTTNCVMB-UHFFFAOYSA-N serotonin Chemical compound C1=C(O)C=C2C(CCN)=CNC2=C1 QZAYGJVTTNCVMB-UHFFFAOYSA-N 0.000 claims abstract description 42
- 230000002093 peripheral effect Effects 0.000 claims abstract description 37
- 230000015556 catabolic process Effects 0.000 claims abstract description 33
- 238000006731 degradation reaction Methods 0.000 claims abstract description 33
- 239000003112 inhibitor Substances 0.000 claims abstract description 32
- 229940076279 serotonin Drugs 0.000 claims abstract description 19
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 18
- 208000002193 Pain Diseases 0.000 claims abstract description 16
- 208000035475 disorder Diseases 0.000 claims abstract description 12
- 239000003814 drug Substances 0.000 claims abstract description 8
- 230000001419 dependent effect Effects 0.000 claims abstract description 6
- 201000010099 disease Diseases 0.000 claims abstract description 6
- 238000002560 therapeutic procedure Methods 0.000 claims abstract description 6
- 238000004519 manufacturing process Methods 0.000 claims abstract description 4
- 230000002265 prevention Effects 0.000 claims abstract description 4
- 150000001413 amino acids Chemical class 0.000 claims description 11
- 239000003954 decarboxylase inhibitor Substances 0.000 claims description 9
- 229940123736 Decarboxylase inhibitor Drugs 0.000 claims description 6
- 108010031676 Kynureninase Proteins 0.000 claims description 6
- 239000002775 capsule Substances 0.000 claims description 6
- 102000005447 kynureninase Human genes 0.000 claims description 6
- 239000002253 acid Substances 0.000 claims description 2
- ULFCBIUXQQYDEI-UHFFFAOYSA-N benserazide hydrochloride Chemical compound Cl.OCC(N)C(=O)NNCC1=CC=C(O)C(O)=C1O ULFCBIUXQQYDEI-UHFFFAOYSA-N 0.000 claims description 2
- 102000016680 Dioxygenases Human genes 0.000 claims 1
- 108010028143 Dioxygenases Proteins 0.000 claims 1
- 210000003169 central nervous system Anatomy 0.000 description 18
- 230000000694 effects Effects 0.000 description 17
- VYFYYTLLBUKUHU-UHFFFAOYSA-N dopamine Chemical compound NCCC1=CC=C(O)C(O)=C1 VYFYYTLLBUKUHU-UHFFFAOYSA-N 0.000 description 14
- WTDRDQBEARUVNC-LURJTMIESA-N L-DOPA Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C(O)=C1 WTDRDQBEARUVNC-LURJTMIESA-N 0.000 description 13
- WTDRDQBEARUVNC-UHFFFAOYSA-N L-Dopa Natural products OC(=O)C(N)CC1=CC=C(O)C(O)=C1 WTDRDQBEARUVNC-UHFFFAOYSA-N 0.000 description 13
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 12
- 239000003795 chemical substances by application Substances 0.000 description 10
- 230000008499 blood brain barrier function Effects 0.000 description 9
- 210000001218 blood-brain barrier Anatomy 0.000 description 9
- 239000002858 neurotransmitter agent Substances 0.000 description 8
- 210000002381 plasma Anatomy 0.000 description 8
- 229960003638 dopamine Drugs 0.000 description 7
- 230000036470 plasma concentration Effects 0.000 description 7
- 239000002243 precursor Substances 0.000 description 4
- 208000027089 Parkinsonian disease Diseases 0.000 description 3
- 206010034010 Parkinsonism Diseases 0.000 description 3
- 239000000654 additive Substances 0.000 description 3
- 210000004369 blood Anatomy 0.000 description 3
- 239000008280 blood Substances 0.000 description 3
- 230000006652 catabolic pathway Effects 0.000 description 3
- 230000000875 corresponding effect Effects 0.000 description 3
- 230000003111 delayed effect Effects 0.000 description 3
- 210000001035 gastrointestinal tract Anatomy 0.000 description 3
- 239000000902 placebo Substances 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 102000004031 Carboxy-Lyases Human genes 0.000 description 2
- 108090000489 Carboxy-Lyases Proteins 0.000 description 2
- 208000020446 Cardiac disease Diseases 0.000 description 2
- 208000000094 Chronic Pain Diseases 0.000 description 2
- 101710116650 FAD-dependent monooxygenase Proteins 0.000 description 2
- 206010028813 Nausea Diseases 0.000 description 2
- 101710128228 O-methyltransferase Proteins 0.000 description 2
- 230000005540 biological transmission Effects 0.000 description 2
- 230000036772 blood pressure Effects 0.000 description 2
- 210000004556 brain Anatomy 0.000 description 2
- 230000007812 deficiency Effects 0.000 description 2
- 239000003797 essential amino acid Substances 0.000 description 2
- 235000020776 essential amino acid Nutrition 0.000 description 2
- 208000019622 heart disease Diseases 0.000 description 2
- 210000003016 hypothalamus Anatomy 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 230000037353 metabolic pathway Effects 0.000 description 2
- 230000008693 nausea Effects 0.000 description 2
- 235000016709 nutrition Nutrition 0.000 description 2
- 230000035764 nutrition Effects 0.000 description 2
- 229940068196 placebo Drugs 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- LDCYZAJDBXYCGN-VIFPVBQESA-N 5-hydroxy-L-tryptophan Chemical compound C1=C(O)C=C2C(C[C@H](N)C(O)=O)=CNC2=C1 LDCYZAJDBXYCGN-VIFPVBQESA-N 0.000 description 1
- 108010087765 Antipain Proteins 0.000 description 1
- 102000003823 Aromatic-L-amino-acid decarboxylases Human genes 0.000 description 1
- 108090000121 Aromatic-L-amino-acid decarboxylases Proteins 0.000 description 1
- 208000009079 Bronchial Spasm Diseases 0.000 description 1
- 208000014181 Bronchial disease Diseases 0.000 description 1
- 206010006482 Bronchospasm Diseases 0.000 description 1
- 208000020401 Depressive disease Diseases 0.000 description 1
- 206010012735 Diarrhoea Diseases 0.000 description 1
- 208000001640 Fibromyalgia Diseases 0.000 description 1
- 238000006424 Flood reaction Methods 0.000 description 1
- 208000018522 Gastrointestinal disease Diseases 0.000 description 1
- 241000282414 Homo sapiens Species 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 1
- -1 L-tryptophan amino acid Chemical class 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 229940123379 Methyltransferase inhibitor Drugs 0.000 description 1
- 208000028017 Psychotic disease Diseases 0.000 description 1
- 206010040880 Skin irritation Diseases 0.000 description 1
- 206010047700 Vomiting Diseases 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 210000004100 adrenal gland Anatomy 0.000 description 1
- 230000000202 analgesic effect Effects 0.000 description 1
- SDNYTAYICBFYFH-TUFLPTIASA-N antipain Chemical compound NC(N)=NCCC[C@@H](C=O)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)N[C@H](C(O)=O)CC1=CC=CC=C1 SDNYTAYICBFYFH-TUFLPTIASA-N 0.000 description 1
- 210000004227 basal ganglia Anatomy 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 239000003543 catechol methyltransferase inhibitor Substances 0.000 description 1
- 150000003943 catecholamines Chemical class 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 230000002860 competitive effect Effects 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 230000002596 correlated effect Effects 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000000378 dietary effect Effects 0.000 description 1
- 238000006073 displacement reaction Methods 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 206010016256 fatigue Diseases 0.000 description 1
- 239000013020 final formulation Substances 0.000 description 1
- 239000000416 hydrocolloid Substances 0.000 description 1
- 230000002260 hypophysiotrophic effect Effects 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000002197 limbic effect Effects 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 239000003697 methyltransferase inhibitor Substances 0.000 description 1
- 230000001095 motoneuron effect Effects 0.000 description 1
- 210000001640 nerve ending Anatomy 0.000 description 1
- 230000001537 neural effect Effects 0.000 description 1
- 230000001722 neurochemical effect Effects 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 231100000957 no side effect Toxicity 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 230000015355 regulation of circadian sleep/wake cycle, sleep Effects 0.000 description 1
- 230000000241 respiratory effect Effects 0.000 description 1
- 210000002345 respiratory system Anatomy 0.000 description 1
- 230000036556 skin irritation Effects 0.000 description 1
- 231100000475 skin irritation Toxicity 0.000 description 1
- IFGCUJZIWBUILZ-UHFFFAOYSA-N sodium 2-[[2-[[hydroxy-(3,4,5-trihydroxy-6-methyloxan-2-yl)oxyphosphoryl]amino]-4-methylpentanoyl]amino]-3-(1H-indol-3-yl)propanoic acid Chemical compound [Na+].C=1NC2=CC=CC=C2C=1CC(C(O)=O)NC(=O)C(CC(C)C)NP(O)(=O)OC1OC(C)C(O)C(O)C1O IFGCUJZIWBUILZ-UHFFFAOYSA-N 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 230000002889 sympathetic effect Effects 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 230000008673 vomiting Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
- A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
- A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Pain & Pain Management (AREA)
- Anesthesiology (AREA)
- Psychiatry (AREA)
- Rheumatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Indole Compounds (AREA)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE102004039196A DE102004039196B4 (de) | 2004-08-12 | 2004-08-12 | Neue Formulierung für L-Tryptophan |
Publications (1)
Publication Number | Publication Date |
---|---|
ZA200700395B true ZA200700395B (en) | 2008-04-30 |
Family
ID=35276634
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ZA200700395A ZA200700395B (en) | 2004-08-12 | 2007-01-12 | Novel formulation for L-tryptophane comprising carbidopa/benserazide |
Country Status (14)
Country | Link |
---|---|
US (1) | US8642639B2 (zh) |
EP (1) | EP1784177B1 (zh) |
JP (1) | JP2008509170A (zh) |
KR (1) | KR101239379B1 (zh) |
CN (1) | CN101022795B (zh) |
AT (1) | ATE429912T1 (zh) |
AU (1) | AU2005270573B2 (zh) |
BR (1) | BRPI0514217A (zh) |
CA (1) | CA2576385C (zh) |
DE (2) | DE102004039196B4 (zh) |
DK (1) | DK1784177T3 (zh) |
RU (1) | RU2377983C2 (zh) |
WO (1) | WO2006015590A2 (zh) |
ZA (1) | ZA200700395B (zh) |
Families Citing this family (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE102004039196B4 (de) * | 2004-08-12 | 2008-07-31 | Dr.Kamprad Kg | Neue Formulierung für L-Tryptophan |
JP6067292B2 (ja) * | 2012-03-19 | 2017-01-25 | サッポロビール株式会社 | セロトニン分泌促進剤 |
US9895353B2 (en) | 2013-09-11 | 2018-02-20 | Zzeemag Inc. | Use of L-tryptophan for the treatment of parasomnias |
CA2959197C (en) * | 2014-09-17 | 2023-03-14 | Herlev Hospital | Vaccine compositions comprising tryptophan 2,3-dioxygenase or fragments thereof |
GB201521541D0 (en) * | 2015-12-07 | 2016-01-20 | Proximagen Ltd | New therapeutic uses of enzyme inhibitors |
EP3386494A1 (en) * | 2015-12-07 | 2018-10-17 | Benevolentai Cambridge Limited | Vap-1 inhibitors for treating pain |
DE102022103658A1 (de) | 2022-02-16 | 2023-08-17 | Joachim Kamprad | Arzneimittelzusammensetzung enthaltend L-Tryptophan (L-Try) und L-5-Hydroxytryptophan (5-HTP) sowie einen peripheren Abbauhemmer |
Family Cites Families (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4424235A (en) | 1981-09-14 | 1984-01-03 | Hoffmann-La Roche Inc. | Hydrodynamically balanced controlled release compositions containing L-dopa and a decarboxylase inhibitor |
CH652025A5 (de) | 1981-09-14 | 1985-10-31 | Hoffmann La Roche | Pharmazeutisches praeparat. |
US4687763A (en) * | 1985-02-25 | 1987-08-18 | Massachusetts Institute Of Technology | Composition and method for increasing levels or release of brain serotonin |
US5188840A (en) * | 1985-09-26 | 1993-02-23 | Chugai Seiyaku Kabushiki Kaisha | Slow-release pharmaceutical agent |
DE3642668A1 (de) * | 1986-12-13 | 1988-06-23 | Kamprad Joachim | Schmerzmittel fuer menschen |
FR2647345B1 (fr) * | 1989-05-25 | 1992-08-28 | Trouillas Paul | Association de l-5-hydroxy-tryptophane et de benserazide a titre de composition pharmaceutique, notamment utile dans le traitement des troubles de l'equilibre et l'ataxie, cerebelleux ou autres, de toutes origines, et son utilisation pour la preparation de ladite composition |
FR2654931B1 (fr) * | 1989-11-24 | 1993-08-27 | Trouillas Paul | Compositions pharmaceutiques possedant une activite sur l'ataxie et les troubles de l'equilibre, cerebelleux ou autres, de toutes origines, comprenant l'association de l-5-hydroxytryptophane et de carbidopa. |
CA2345815C (en) * | 1998-10-09 | 2011-02-08 | General Mills, Inc. | Encapsulation of sensitive liquid components into a matrix to obtain discrete shelf-stable particles |
US6207699B1 (en) * | 1999-06-18 | 2001-03-27 | Richard Brian Rothman | Pharmaceutical combinations for treating obesity and food craving |
DE102004039196B4 (de) * | 2004-08-12 | 2008-07-31 | Dr.Kamprad Kg | Neue Formulierung für L-Tryptophan |
-
2004
- 2004-08-12 DE DE102004039196A patent/DE102004039196B4/de not_active Expired - Fee Related
-
2005
- 2005-08-12 CN CN2005800272240A patent/CN101022795B/zh active Active
- 2005-08-12 EP EP05774433A patent/EP1784177B1/de active Active
- 2005-08-12 JP JP2007525165A patent/JP2008509170A/ja active Pending
- 2005-08-12 RU RU2007103773/15A patent/RU2377983C2/ru active
- 2005-08-12 KR KR1020077005358A patent/KR101239379B1/ko active IP Right Grant
- 2005-08-12 CA CA2576385A patent/CA2576385C/en active Active
- 2005-08-12 AT AT05774433T patent/ATE429912T1/de active
- 2005-08-12 BR BRPI0514217-2A patent/BRPI0514217A/pt not_active Application Discontinuation
- 2005-08-12 WO PCT/DE2005/001428 patent/WO2006015590A2/de active Application Filing
- 2005-08-12 DE DE502005007201T patent/DE502005007201D1/de active Active
- 2005-08-12 AU AU2005270573A patent/AU2005270573B2/en not_active Ceased
- 2005-08-12 US US11/573,633 patent/US8642639B2/en active Active
- 2005-08-12 DK DK05774433T patent/DK1784177T3/da active
-
2007
- 2007-01-12 ZA ZA200700395A patent/ZA200700395B/en unknown
Also Published As
Publication number | Publication date |
---|---|
CN101022795A (zh) | 2007-08-22 |
US8642639B2 (en) | 2014-02-04 |
RU2377983C2 (ru) | 2010-01-10 |
DK1784177T3 (da) | 2009-08-24 |
EP1784177B1 (de) | 2009-04-29 |
BRPI0514217A (pt) | 2008-06-03 |
DE102004039196B4 (de) | 2008-07-31 |
DE502005007201D1 (de) | 2009-06-10 |
DE102004039196A1 (de) | 2006-03-02 |
CA2576385C (en) | 2016-01-05 |
AU2005270573B2 (en) | 2011-03-31 |
KR20070048777A (ko) | 2007-05-09 |
CN101022795B (zh) | 2012-02-15 |
JP2008509170A (ja) | 2008-03-27 |
WO2006015590A3 (de) | 2006-05-26 |
AU2005270573A1 (en) | 2006-02-16 |
EP1784177A2 (de) | 2007-05-16 |
ATE429912T1 (de) | 2009-05-15 |
KR101239379B1 (ko) | 2013-03-05 |
US20110288145A1 (en) | 2011-11-24 |
RU2007103773A (ru) | 2008-09-20 |
WO2006015590A2 (de) | 2006-02-16 |
CA2576385A1 (en) | 2006-02-16 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US11773051B2 (en) | S-enantiomers of beta-hydroxybutyrate and butanediol and methods for using same | |
EP2468271B1 (en) | Pharmaceutical composition comprising droxidopa for the treatment of fibromyalgia | |
CA2576385C (en) | Novel formulation for l-tryptophane comprising carbidopa/benserazide | |
AU765038B2 (en) | Method for the treatment of insomnia | |
EP2363124B1 (en) | Pharmaceutical compositions comprising droxidopa | |
Stocchi | The hypothesis of the genesis of motor complications and continuous dopaminergic stimulation in the treatment of Parkinson's disease | |
JP2007509146A (ja) | レボドーパの持続効果のための組成物及び投与形 | |
US20060052455A1 (en) | Composition for preventing treating the xepression of clinical symptom in disease caused by mitochondrial dysfunction | |
JPH025732B2 (zh) | ||
US20070292536A1 (en) | Composition and method for treating patients with high neurotransmitter levels | |
US20110117070A1 (en) | Compositions and methods for treating headache | |
JPH02500596A (ja) | 医薬組成物 | |
BG65735B1 (bg) | Приложение на алфа-липоева киселина или нейни прозводни за лечение на мигрена | |
US7915262B2 (en) | Combination preparations comprising SLV308 and a dopamine agonist | |
KR20030019444A (ko) | 안지오텐신 ⅱ 길항물질의 신규한 용도 | |
WO2023156275A1 (en) | Pharmaceutical composition and medicament comprising l-tryptophan, l-5-hydroxytryptophan and a peripheral degradation inhibitor | |
US5216019A (en) | Pain killer | |
MX2011013989A (es) | Combinacion farmaceutica. |